Novartis To Payers: Entresto Works Or You Get A Discount
This article was originally published in Scrip
Performance-based reimbursement agreements with US payers, like the deals that Novartis AG recently struck with Cigna Corp. and Aetna Inc. for the heart failure drug Entresto (sacubitril/valsartan), are rare, but Novartis US Head Christi Shaw said she's hopeful that the concept will catch on.
You may also be interested in...
Elisabeth Aloy and David Pistor, healthcare and life sciences advisors at Monitor Deloitte, outline five design principles to create a value-based care project.
The promise of outcomes-based contracts for biopharmaceuticals has yet to be realized in the US. Although precise numbers are hard to come by, payers and manufacturers agree the field is still nascent. However, they don’t seem to be giving up on the idea.
Duke’s Mark McClellan made a strong pitch for such contracting during a Capitol Hill debate on cost control with Johns Hopkins’ Gerard Anderson.